Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $10,655,987.10 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 17,610 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total value of $10,655,987.10. Following the transaction, the chief executive officer owned 615,802 shares of the company’s stock, valued at approximately $372,627,948.22. The trade was a 2.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Medpace Price Performance

Shares of MEDP stock traded down $8.52 during trading hours on Wednesday, hitting $596.98. The stock had a trading volume of 310,338 shares, compared to its average volume of 355,204. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The stock’s 50-day moving average price is $528.36 and its two-hundred day moving average price is $491.85. The stock has a market capitalization of $16.66 billion, a price-to-earnings ratio of 34.99, a PEG ratio of 2.69 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the company earned $3.10 earnings per share. The firm’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

MEDP has been the topic of several research reports. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Finally, Robert W. Baird upped their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $584.18.

Hedge Funds Weigh In On Medpace

Large investors have recently modified their holdings of the stock. Johnson Financial Group Inc. bought a new stake in Medpace in the second quarter worth $27,000. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the fourth quarter valued at $30,000. Allied Private Wealth LLC purchased a new stake in shares of Medpace in the second quarter valued at $31,000. Finally, Kilter Group LLC bought a new stake in shares of Medpace in the 2nd quarter worth about $31,000. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.